Parkinson’s UK is pleased to announce a new project worth £1.2million to fund essential research towards new treatment that could both improve symptoms and slow the progression of Parkinson’s.
We're partnering with US company Neurolixis to accelerate the development of a drug that could prevent dyskinesia, a debilitating side effect of Parkinson's medication.
New figures from Parkinson's UK show that more than 12,000 Scots are now living with Parkinson's, and numbers are continuing to rise.
Researchers in Japan have discovered that people with Parkinson's may have lower levels of caffeine in their blood after drinking tea and coffee.
Research supported by Parkinson's UK has identified a medicine used to treat tapeworm infections which could lead to new treatments for people with Parkinson's.